The Management Board of Selvita S.A. with its registered office in Krakow (the “Issuer”) hereby corrects an obvious clerical error contained in the current report No. 42/2022 dated December 23, 2022, consisting in a misrepresentation of the date and amount concerning the statement of work, which was the subject of the report. The correct version of the report can be found below.

The Management Board of Selvita S.A. with its registered office in Krakow (the “Issuer”) hereby announces that the company affiliated with Selvita – Selvita d.o.o. (the “Subsidiary”) with its registered office in Zagreb, Croatia has received on December 22, 2022 a statement of work with a total value of EUR 2.639.501,00 (PLN 12.313.536,11 converted at the exchange rate of the National Bank of Poland of December 22, 2022 EUR 1=PLN 4.6551) under a framework agreement executed on 1st October 2018 (“Statement of Work”) between the Subsidiary and one of the largest pharmaceutical companies in Europe (the “Client”). The scope of the work is to identify compounds for the treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases. The Subsidiary, in its laboratories in Zagreb, will provide services in the area of medicinal chemistry, computer aided drug design (CADD), in vitro and in vivo pharmacology, ADME and DMPK profiling, Phys-Chem profiling, and analytics.

The services under this Statement of Work will be provided over the next 12 months.

Taking into account value of the Statement of Work, its scope and the continuation of collaboration with the Client, the Issuer’s Management Board considers it to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position as a provider of Integrated Drug Discovery services.

Legal basis: Art. 17.1 of MAR

Representatives of the Company:     

• Bogusław Sieczkowski – President of the Management Board
• Miłosz Gruca – Vicepresident of the Management Board